Letter to the editorDiagnosing nonimmediate reactions to cephalosporins
References (10)
- et al.
Diagnosis and management of drug hypersensitivity reactions
J Allergy Clin Immunol
(2011) Delayed drug hypersensitivity reactions
Ann Intern Med
(2003)- et al.
Evaluation of skin test reactions in patients with non-immediate type drug eruptions
J Dermatol
(1990) - et al.
The usefulness of skin tests to prove drug hypersensitivity
Br J Dermatol
(2005) - et al.
Diagnosing hypersensitivity reactions to cephalosporins in children
Pediatrics
(2008)
Cited by (58)
Diagnosis and selection of alternative antibiotics in beta-lactams hypersensitivity reactions: Current recommendations and challenges
2023, International ImmunopharmacologyDrug allergy: A 2022 practice parameter update
2022, Journal of Allergy and Clinical ImmunologyDiagnostic Approach of Hypersensitivity Reactions to Cefazolin in a Large Prospective Cohort
2021, Journal of Allergy and Clinical Immunology: In PracticeCephalosporin Hypersensitivity: Descriptive Analysis, Cross-Reactivity, and Risk Factors
2021, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :Also, throughout the years, the panel of tested cephalosporins slightly changed, according to removal of some cephalosporins from the French market and the increased utilization of others. Few studies mainly carried out by Romano et al3-7 and Antunez et al2 have evaluated subjects with cephalosporin hypersensitivity and have assessed cross-reactivity with penicillins, on the basis on ST, serum specific IgE assays, and DPT. They found a rate of cross-reactivity ranging from 13.3% to 40.1% in cephalosporin hypersensitive patients (for the most majority of them involving ceftriaxone, ceftazidime, cefaclor, and cefazolin) and penicillin reagents, including PPL, MDM, benzylpenicillin, amoxicillin, and ampicillin.
Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: General Concepts
2020, Journal of Allergy and Clinical Immunology: In PracticeDelabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?
2020, Journal of Allergy and Clinical Immunology: In Practice
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.